Medtronic PLC (NYSE:MDT - Get Free Report) EVP Harry Skip Kiil sold 52,524 shares of the stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $97.71, for a total value of $5,132,120.04. Following the transaction, the executive vice president directly owned 32,768 shares of the company's stock, valued at $3,201,761.28. This trade represents a 61.58% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.
Medtronic Trading Up 0.3%
MDT opened at $96.97 on Friday. The company's 50 day moving average price is $98.95 and its two-hundred day moving average price is $96.83. The firm has a market capitalization of $124.50 billion, a price-to-earnings ratio of 27.01, a PEG ratio of 2.43 and a beta of 0.71. Medtronic PLC has a fifty-two week low of $79.55 and a fifty-two week high of $106.33. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.54 and a quick ratio of 1.80.
Medtronic (NYSE:MDT - Get Free Report) last posted its quarterly earnings data on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share for the quarter, topping the consensus estimate of $1.34 by $0.02. The company had revenue of $9.02 billion during the quarter, compared to analysts' expectations of $8.89 billion. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. Medtronic's revenue for the quarter was up 5.8% compared to the same quarter last year. During the same period in the prior year, the company posted $1.38 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, research analysts predict that Medtronic PLC will post 5.46 earnings per share for the current year.
Medtronic Announces Dividend
The firm also recently announced a quarterly dividend, which was paid on Friday, January 16th. Shareholders of record on Friday, December 26th were issued a dividend of $0.71 per share. The ex-dividend date of this dividend was Friday, December 26th. This represents a $2.84 dividend on an annualized basis and a yield of 2.9%. Medtronic's payout ratio is presently 79.11%.
Hedge Funds Weigh In On Medtronic
Hedge funds and other institutional investors have recently modified their holdings of the business. Monetary Solutions Ltd purchased a new position in shares of Medtronic in the 4th quarter valued at $27,000. Corundum Trust Company INC bought a new stake in Medtronic during the third quarter valued at about $27,000. Lodestone Wealth Management LLC purchased a new position in Medtronic in the fourth quarter valued at about $27,000. Anfield Capital Management LLC raised its holdings in Medtronic by 410.7% in the fourth quarter. Anfield Capital Management LLC now owns 286 shares of the medical technology company's stock worth $27,000 after purchasing an additional 230 shares in the last quarter. Finally, Board of the Pension Protection Fund purchased a new stake in shares of Medtronic during the fourth quarter valued at about $29,000. 82.06% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
MDT has been the topic of several recent analyst reports. CICC Research started coverage on Medtronic in a research note on Friday, January 30th. They issued an "outperform" rating on the stock. UBS Group restated a "neutral" rating and set a $104.00 price target on shares of Medtronic in a research note on Wednesday, February 4th. Leerink Partners reduced their price objective on shares of Medtronic from $120.00 to $119.00 and set an "outperform" rating for the company in a research note on Wednesday, February 18th. Truist Financial dropped their price objective on shares of Medtronic from $107.00 to $103.00 and set a "hold" rating for the company in a report on Wednesday, February 18th. Finally, Morgan Stanley lifted their price objective on shares of Medtronic from $107.00 to $117.00 and gave the stock an "overweight" rating in a research note on Wednesday, November 19th. One research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have assigned a Hold rating to the company. Based on data from MarketBeat.com, Medtronic currently has a consensus rating of "Moderate Buy" and a consensus target price of $110.84.
View Our Latest Stock Analysis on MDT
Medtronic Company Profile
(
Get Free Report)
Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.
Medtronic's offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
